(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 9. At low concentrations, specific inhibitors of myosin II activity abolish supervillin-mediated decreases in spreading of COS7 cells. Percentages of spread COS7 cells expressing either EGFP-SV or EGFP at 30 minutes after plating on fibronectin in the presence of inhibitors of myosin function: (A) MHC ATPase inhibitor, blebbistatin, **P=0.003 (20 µM versus 0 µM for EGFP-SV); (B) MLCK inhibitor, ML-7, **P=0.002 (1.0 µM versus 0 µM for EGFP-SV); (C) MEK inhibitor, U0126, *P=0.014 (2.5 µM versus 0 µM for EGFP-SV); (D) Rho kinase inhibitor, Y-27632, no significant effects. Means±s.e.m.; 100 cells per data point per experiment, n=4.